270 related articles for article (PubMed ID: 38356551)
1. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
3. Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.
Tang C; Fan Y; Zhu S
BMC Urol; 2024 Mar; 24(1):69. PubMed ID: 38532369
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
Chen L; Lin J; Wen Y; Chen Y; Chen CB
Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
[TBL] [Abstract][Full Text] [Related]
6. Disulfidptosis and ferroptosis related genes predict prognosis and personalize treatment for hepatocellular carcinoma.
Liu JF; Huang L; Zhou XP; Li CR; Liu MF; Liang YH; Yu QH; Wu JR
Transl Cancer Res; 2024 Feb; 13(2):496-514. PubMed ID: 38482398
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of scRNA-seq and bulk RNA-seq reveal the characteristics of disulfidptosis and a prognostic signature in BLCA.
Deng H; Cheng F; Cheng S
Aging (Albany NY); 2024 Mar; 16(6):5751-5771. PubMed ID: 38507521
[TBL] [Abstract][Full Text] [Related]
8. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis.
Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L
Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
Front Oncol; 2023; 13():972558. PubMed ID: 37064115
[TBL] [Abstract][Full Text] [Related]
10. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
[TBL] [Abstract][Full Text] [Related]
12. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
Front Genet; 2021; 12():696912. PubMed ID: 34512722
[No Abstract] [Full Text] [Related]
13. Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.
Zhong F; Jiang J; Yao FY; Liu J; Shuai X; Wang XL; Huang B; Wang X
Front Pharmacol; 2023; 14():1272701. PubMed ID: 38053840
[No Abstract] [Full Text] [Related]
14. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
Tan Z; Fu S; Zuo J; Wang J; Wang H
Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
[TBL] [Abstract][Full Text] [Related]
15. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma.
Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G
Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725
[TBL] [Abstract][Full Text] [Related]
17. Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer.
Wang D; Ning H; Wu H; Song Y; Chu Y; Liu F; Zhao Z; Wu F; Lyu J
Curr Urol; 2023 Dec; 17(4):236-245. PubMed ID: 37994343
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
20. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
Wan Z; Wang Y; Li C; Zheng D
Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
